surmount 2 tirzepatide (ZEPBOUND) Approved for Chronic Weight Management in Adults with Obesity ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or SURMOUNT-2: Tirzepatide Demonstrates Body Weight-Lowering

There is no prior authorization process, no insurance denial risk, and access begins within days rather than weeks

Stigma Around GLP-1s

Hynes highlights concerning findings from animal studies: There was an increased risk of miscarriage and fetal abnormalities, she said while also noting that animal studies do not always correlate with human studies

Peak results typically appear over 6 to 12 months, with average reductions of 15 to 25 pounds or more depending on adherence

Diabetes mellitus represents the most significant risk factor for peripheral neuropathy in the UK, with approximately 50% of people with long-standing diabetes eventually developing some degree of nerve damage, according to Diabetes UK